Nexavar in India has reduced the price of 13621079267 Nexavar first-line liver and kidney drug price

d%> d= _ d=> Histological diagnosis of kidney cancer can be obtained after surgery or biopsy. According to the World Health Organization, kidney cancer is mainly divided into three main types: clear cell carcinoma (-%) [banned word] shape cell carcinoma ( -%) and chromophobe carcinoma (-%). Prognostic scoring system for risk stratification of metastatic stage renal cancer.
Special Statement
The renal cancer described in this article mainly refers to the treatment of renal cell carcinoma, which is mainly clear cell. Nowadays, clinically, renal cancer treatment options are generally divided into two categories: cytokines and targeted drugs. Targeted therapies such as Nexavar (sorafenib), Sutent (sunitinib) and the latest drugs axitinib and pazopanib, etc., these targeted drugs for kidney cancer have been widely used in clinical practice and Excellent results were achieved. < .d/ Nexavar
Cytokine therapy for renal cell carcinoma
As of 2018, the systemic treatment of metastatic renal cancer is limited to cytokine therapy or new renal cancer targeted drugs. Over the past year there have been multiple clinical trials of various combinations of different doses of interferon in patients with metastatic, recurrent or unresectable clear cell carcinoma.
High-dose - for first-line treatment of clear cell-based type
-based immunotherapy for the treatment of advanced renal cell carcinoma. It has been reported that a small number of patients can achieve durable complete remission or partial remission. It is difficult to obtain sustained complete remission with treatment. US D-approved and high-dose intravenous-treatment are no longer used in US medical centers and direct comparisons cannot be made.
A multi-center study from France showed that the prognosis of high-intensity or -treatment was similar, while the combination treatment group achieved a higher response rate at the expense of severe toxicity. High Dose-Associated with Severe Toxicity Attempts to identify tumor characteristics or patient factors that better predict patient response have also been unsuccessful.
The best selection principle for patients receiving high-dose treatment is largely based on drug safety, including the patient's general behavioral status, medical-related complications, tumor histology (clear cell mainly) score or postoperative and immunotherapy Survival scores and patient attitudes toward treatment risks.
Drug Shipping (Iressa India Direct Shopping Online) Recommendation: High dose - can be used as evidence to recommend as a first-line treatment option for patients with hemorrhagic recurrent or inoperable stage IV metastatic renal cancer.
Special reminder: - First, it was found to have anti-tumor activity in a mouse tumor model and was later used in kidney cancer patients. - and combination have reported an objective effective rate of -%. Although some patients can benefit from these drugs, for the vast majority of patients, the therapeutic benefits are mild and the side effects are relatively large.
Targeted therapy
Tyrosine kinase inhibitors and anti-targeted therapies are widely used in the first- and second-line treatment of renal cancer.
So far, the U.S. Food and Drug Administration (D) has approved seven targeted drugs for the treatment of metastatic rheumatoid arthritis: sunitinib (Sutent), sorafenib (Nexavar), pazopag nib, axitinib, temsirolimus, everolimus, bevacizumab combined with interferon.
Special reminder for drug delivery: Tumor histopathology and risk stratification are important for the selection of targeted therapy. As the main treatment option for renal cancer, targeted drug therapy has been proven to have excellent effects. Pharmaceutical Mail will introduce these seven targeted drugs in subsequent articles. Please continue to pay attention.